Clinical Research Papers:

Single nucleotide polymorphisms in MLH1 predict poor prognosis of hepatocellular carcinoma in a Chinese population

Xiaonian Zhu, Wei Liu, Xiaoqiang Qiu, Zhigang Wang, Chao Tan, Chunhua Bei, Linyuan Qin, Yuan Ren and Shengkui Tan _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:80039-80049. https://doi.org/10.18632/oncotarget.16899

Metrics: PDF 1544 views  |   HTML 1731 views  |   ?  


Xiaonian Zhu1,*, Wei Liu1,*, Xiaoqiang Qiu2, Zhigang Wang1, Chao Tan1, Chunhua Bei1, Linyuan Qin1, Yuan Ren1 and Shengkui Tan1

1Department of Epidemiology and Statistics, School of Public Health, Guilin Medical University, Guilin 541004, Guangxi, People’s Republic of China

2Department of Epidemiology, School of Public Health, Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Shengkui Tan, email: [email protected]

Keywords: MLH1, HCC, SNP, risk, prognosis

Received: November 04, 2016     Accepted: March 27, 2017     Published: April 06, 2017


Hepatocellular carcinoma (HCC) is a malignant cancer causing deleterious health effect worldwide, especially in China. So far clinical cure rate and long-term survival rate of HCC remains low. Most HCC patients after cancer resection have recurrence or metastasis within 5 years. This study aims to explore the genetic association of mutL homolog 1 (MLH1) polymorphisms with HCC risk and prognosis. Four candidate MLH1 polymorphisms, rs1800734, rs10849, rs3774343 and rs1540354 were studied from a hospital-based case-control study including 1,036 cases (HCC patients) and 1,036 controls (non-HCC patients) in Guangxi, China. All these SNPs interacted with environmental risk factors, such as HBV infection, alcohol intake and smoking in the pathogenesis of HCC. However, only rs1800734 had significant difference between cases and controls. Compared to the AA genotype, patients with AG, GG and AG/GG genotype of rs1800734 had an increased risk of HCC [ORs (95% CI) = 1.217 (1.074~1.536), 1.745 (1.301~2.591) and 1.291 (1.126~1.687)] and a decreased survival time [co-dominant, HR (95% CI) = 1.553 (1.257~1.920); dominant, HR (95% CI) = 2.207 (1.572~3.100)]. Furthermore, we found that tumor number, tumor staging, metastasis and rs1800734 were associated with the overall survival of HCC patients by multivariate COX regression analysis. No significant difference was found between the other three MLH1 polymorphisms with HCC risk and prognosis. Our study suggests MLH1 SNP, rs1800734 as a new predictor for poor prognosis of HCC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16899